170105-16-5
Chemical Structure
Imidafenacin
Synonym(s): KRP-197; ONO-8025
- CAS No.: 170105-16-5
- Formula:C20H21N3O
- Molecular Weight:319.40
IUPAC Name: 4-(2-methyl-1H-imidazol-1-yl)-2,2-diphenylbutanamide
InChIKey: SQKXYSGRELMAAU-UHFFFAOYSA-N
SMILES: NC(C(C1=CC=CC=C1)(C2=CC=CC=C2)CCN3C(C)=NC=C3)=O
Biological Activity: Imidafenacin (KRP-197; ONO-8025) is an orally active inhibitor of muscarinic (mAChR) M1 and M3 receptors. Imidafenacin potently inhibits bladder contraction in vivo and exerts an antidiuretic effect by enhancing the signaling pathway of vasopressin (antidiuretic hormone). Imidafenacin can be used in research related to overactive bladder[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Imidafenacin | 99.26% | Imidafenacin (KRP-197; ONO-8025) is an orally active inhibitor of muscarinic (mAChR) M1 and M3 receptors. Imidafenacin potently inhibits bladder contraction in vivo and exerts an antidiuretic effect by enhancing the signaling pathway of vasopressin (antidiuretic hormone). Imidafenacin can be used in research related to overactive bladder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Imidafenacin (Standard) | ≥98% | Imidafenacin (KRP-197; ONO-8025) is an orally active inhibitor of muscarinic (mAChR) M1 and M3 receptors. Imidafenacin potently inhibits bladder contraction in vivo and exerts an antidiuretic effect by enhancing the signaling pathway of vasopressin (antidiuretic hormone). Imidafenacin can be used in research related to overactive bladder. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Yamazaki T, et al. Imidafenacin exerts the antidiuretic effect by enhancing vasopressin-related responses in orally water-loaded rats. Eur J Pharmacol. 2016;791:72-77. [Content Brief]
-
[2]. Kobayashi F, et al. Pharmacological effects of imidafenacin (KRP-197/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Arzneimittelforschung. 2007 Mar;57(03):147-54.
Keywords
